AUB ScholarWorks

Current strategies in antifungal therapy for invasive aspergillosis in immunocompromised patients following hematopoietic stem cell transplantation

Show simple item record

dc.contributor.author El Chakhtoura N.G.
dc.contributor.author Kanafani Z.A.
dc.contributor.editor
dc.date 2010
dc.date.accessioned 2017-10-05T15:39:36Z
dc.date.available 2017-10-05T15:39:36Z
dc.date.issued 2010
dc.identifier
dc.identifier.isbn
dc.identifier.issn 17533783
dc.identifier.uri http://hdl.handle.net/10938/16989
dc.description.abstract Shifting epidemiological trends in invasive fungal infections (IFI) have recently surfaced, with an increase in mould infections, which currently constitute the bulk of IFI. Many changes have contributed to this shift, including the widespread use of fluconazole prophylaxis, which successfully prevents Candida infections but not other IFI, as well as recent advances in hematopoietic stem cell transplant (HSCT) practices, with ever-growing immunosuppressive protocols and treatments for graft-versus-host disease. Allogeneic HSCT recipients are the subset of patients at the greatest risk, with an incidence of proven or probable IFI of 5-18percent and a crude mortality rate of 70-93percent. These alarming numbers have triggered unprecedented research into preventing these infections as well as identifying antifungal agents or combinations that would prove successful for treatment in such a high-risk population. In this review, the available evidence behind the use of various antifungal agents and their combinations as first-line, salvage, and prophylactic therapies for invasive aspergillosis (IA), with a special interest in HSCT recipients, is assessed. Various approaches for the management of such patients with IA in an era of growing antifungal resistance and development of new antifungal agents are also evaluated.
dc.format.extent
dc.format.extent Pages: (54-65)
dc.language English
dc.relation.ispartof Publication Name: Journal of Invasive Fungal Infections; Publication Year: 2010; Volume: 4; no. 2; Pages: (54-65);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Current strategies in antifungal therapy for invasive aspergillosis in immunocompromised patients following hematopoietic stem cell transplantation
dc.type Review
dc.contributor.affiliation El Chakhtoura, N.G., Division of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Kanafani, Z.A., Division of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.authorAddress Kanafani, Z.A.; Division of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon; email: zk10@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Infectious Diseases;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Infectious Diseases
dc.contributor.authorEmail
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited
dc.description.citedCount
dc.description.citedTotWOSCount
dc.description.citedWOSCount
dc.format.extentCount 12
dc.identifier.articleNo
dc.identifier.coden
dc.identifier.pubmedID
dc.identifier.scopusID 83455224457
dc.identifier.url
dc.publisher.address
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr
dc.relation.ispartOfIssue 2
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Journal of Invasive Fungal Infections
dc.relation.ispartofPubTitleAbbr J. Invasive Fungal Infect.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 4
dc.source.ID
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS anidulafungin, 166663-25-8
dc.subject.otherChemCAS caspofungin, 189768-38-5
dc.subject.otherChemCAS fluconazole, 86386-73-4
dc.subject.otherChemCAS itraconazole, 84625-61-6
dc.subject.otherChemCAS micafungin, 208538-73-2
dc.subject.otherChemCAS posaconazole, 171228-49-2
dc.subject.otherChemCAS ravuconazole, 182760-06-1
dc.subject.otherChemCAS voriconazole, 137234-62-9
dc.subject.otherIndex amphotericin B deoxycholate
dc.subject.otherIndex amphotericin B lipid complex
dc.subject.otherIndex anidulafungin
dc.subject.otherIndex antifungal agent
dc.subject.otherIndex caspofungin
dc.subject.otherIndex fluconazole
dc.subject.otherIndex itraconazole
dc.subject.otherIndex micafungin
dc.subject.otherIndex posaconazole
dc.subject.otherIndex ravuconazole
dc.subject.otherIndex voriconazole
dc.subject.otherIndex antifungal resistance
dc.subject.otherIndex antifungal therapy
dc.subject.otherIndex antimicrobial therapy
dc.subject.otherIndex aspergillosis
dc.subject.otherIndex drug cost
dc.subject.otherIndex drug megadose
dc.subject.otherIndex gastrointestinal disease
dc.subject.otherIndex hematopoietic stem cell transplantation
dc.subject.otherIndex human
dc.subject.otherIndex hypertriglyceridemia
dc.subject.otherIndex hypokalemia
dc.subject.otherIndex immunocompromised patient
dc.subject.otherIndex invasive aspergillosis
dc.subject.otherIndex liver toxicity
dc.subject.otherIndex nonhuman
dc.subject.otherIndex review
dc.subject.otherIndex salvage therapy
dc.subject.otherIndex treatment response
dc.subject.otherKeywordPlus
dc.subject.otherWOS


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account